Anavex Life Sciences Reports Newly Published Data on Alzheimer’s Disease Research Demonstrate the Neuroprotective Features of the Sigma-1 Receptor
Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in Washington, DC
Efficacy of ANAVEX 2-73, a Sigma-1 receptor agonist, in the MECP2 mouse model of Rett syndrome
Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX®2- 73 at 2017 Clinical Trials on Alzheimer’s Disease Meeting
Anavex Life Sciences will be presenting data at the CTAD conference in Boston, Massachusetts on Saturday November 4th at 3:30 PM.
Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference
Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017
Anavex Life Sciences will be presenting at 11am this year at the OktoberINVESTfest. The day long event will be held at the New York Academy of Sciences on 250 Greenwich Street in New York City from 8am to 6pm.